331 related articles for article (PubMed ID: 24155235)
1. Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free β-thalassemia induced pluripotent stem cells.
Ma N; Liao B; Zhang H; Wang L; Shan Y; Xue Y; Huang K; Chen S; Zhou X; Chen Y; Pei D; Pan G
J Biol Chem; 2013 Nov; 288(48):34671-9. PubMed ID: 24155235
[TBL] [Abstract][Full Text] [Related]
2. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
[TBL] [Abstract][Full Text] [Related]
3. Factor-induced Reprogramming and Zinc Finger Nuclease-aided Gene Targeting Cause Different Genome Instability in β-Thalassemia Induced Pluripotent Stem Cells (iPSCs).
Ma N; Shan Y; Liao B; Kong G; Wang C; Huang K; Zhang H; Cai X; Chen S; Pei D; Chen N; Pan G
J Biol Chem; 2015 May; 290(19):12079-89. PubMed ID: 25795783
[TBL] [Abstract][Full Text] [Related]
4. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
[TBL] [Abstract][Full Text] [Related]
5. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
Xu P; Tong Y; Liu XZ; Wang TT; Cheng L; Wang BY; Lv X; Huang Y; Liu DP
Sci Rep; 2015 Jul; 5():12065. PubMed ID: 26156589
[TBL] [Abstract][Full Text] [Related]
6. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
[TBL] [Abstract][Full Text] [Related]
7. Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice.
Wang Y; Zheng CG; Jiang Y; Zhang J; Chen J; Yao C; Zhao Q; Liu S; Chen K; Du J; Yang Z; Gao S
Cell Res; 2012 Apr; 22(4):637-48. PubMed ID: 22310243
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of β-Globin Gene Expression in Thalassemic IVS2-654 Induced Pluripotent Stem Cell-Derived Erythroid Cells by Modified U7 snRNA.
Phanthong P; Borwornpinyo S; Kitiyanant N; Jearawiriyapaisarn N; Nuntakarn L; Saetan J; Nualkaew T; Sa-Ngiamsuntorn K; Anurathapan U; Dinnyes A; Kitiyanant Y; Hongeng S
Stem Cells Transl Med; 2017 Apr; 6(4):1059-1069. PubMed ID: 28213976
[TBL] [Abstract][Full Text] [Related]
9. Combining Single Strand Oligodeoxynucleotides and CRISPR/Cas9 to Correct Gene Mutations in β-Thalassemia-induced Pluripotent Stem Cells.
Niu X; He W; Song B; Ou Z; Fan D; Chen Y; Fan Y; Sun X
J Biol Chem; 2016 Aug; 291(32):16576-85. PubMed ID: 27288406
[TBL] [Abstract][Full Text] [Related]
10. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac.
Xie F; Ye L; Chang JC; Beyer AI; Wang J; Muench MO; Kan YW
Genome Res; 2014 Sep; 24(9):1526-33. PubMed ID: 25096406
[TBL] [Abstract][Full Text] [Related]
11. Correction of Hemoglobin E/Beta-Thalassemia Patient-Derived iPSCs Using CRISPR/Cas9.
Wattanapanitch M
Methods Mol Biol; 2021; 2211():193-211. PubMed ID: 33336279
[TBL] [Abstract][Full Text] [Related]
12. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs.
Sun N; Zhao H
Biotechnol Bioeng; 2014 May; 111(5):1048-53. PubMed ID: 23928856
[TBL] [Abstract][Full Text] [Related]
13. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases.
Sebastiano V; Maeder ML; Angstman JF; Haddad B; Khayter C; Yeo DT; Goodwin MJ; Hawkins JS; Ramirez CL; Batista LF; Artandi SE; Wernig M; Joung JK
Stem Cells; 2011 Nov; 29(11):1717-26. PubMed ID: 21898685
[TBL] [Abstract][Full Text] [Related]
14. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.
Huang X; Wang Y; Yan W; Smith C; Ye Z; Wang J; Gao Y; Mendelsohn L; Cheng L
Stem Cells; 2015 May; 33(5):1470-9. PubMed ID: 25702619
[TBL] [Abstract][Full Text] [Related]
15. Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.
Pavani G; Fabiano A; Laurent M; Amor F; Cantelli E; Chalumeau A; Maule G; Tachtsidi A; Concordet JP; Cereseto A; Mavilio F; Ferrari G; Miccio A; Amendola M
Blood Adv; 2021 Mar; 5(5):1137-1153. PubMed ID: 33635334
[TBL] [Abstract][Full Text] [Related]
16. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
[TBL] [Abstract][Full Text] [Related]
17. Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology.
Li L; Yi H; Liu Z; Long P; Pan T; Huang Y; Li Y; Li Q; Ma Y
Stem Cell Res Ther; 2022 Mar; 13(1):102. PubMed ID: 35255977
[TBL] [Abstract][Full Text] [Related]
18. One-Step Biallelic and Scarless Correction of a β-Thalassemia Mutation in Patient-Specific iPSCs without Drug Selection.
Liu Y; Yang Y; Kang X; Lin B; Yu Q; Song B; Gao G; Chen Y; Sun X; Li X; Bu L; Fan Y
Mol Ther Nucleic Acids; 2017 Mar; 6():57-67. PubMed ID: 28325300
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.
Dever DP; Bak RO; Reinisch A; Camarena J; Washington G; Nicolas CE; Pavel-Dinu M; Saxena N; Wilkens AB; Mantri S; Uchida N; Hendel A; Narla A; Majeti R; Weinberg KI; Porteus MH
Nature; 2016 Nov; 539(7629):384-389. PubMed ID: 27820943
[TBL] [Abstract][Full Text] [Related]
20. Hb Knossos (HBB: c.82G > T), β-globin CD 5 (-CT) (HBB: c.17_18delCT) and δ-globin CD 59 (-a) (HBD: c.179delA) mutations in a Syrian patient with β-thalassemia intermedia.
Moassas F; Nweder MS; Murad H
BMC Pediatr; 2019 Feb; 19(1):61. PubMed ID: 30777047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
